13 June 2005 | News
"With the launch of ERIG, the institute would be addressing all the three areas of category-III animal bite management that includes wound management, administration of rabies immunoglobulin and administration of anti-rabies vaccine," said Dinar A Kumar, general manager, HBI.
He added, "At present, two types of rabies immunoglobulin were available the world over, human (HRIG) or equine (ERIG) origin. As against the imported drug price of Rs 450 per dose, HBI plans to sell the product at Rs 350 per dose. The institute expects to garner a significant share in the Rs 60-crore plus Indian RIG market."
The Hyderabad-based VINS Bio Products Pvt Ltd has developed the drug ERIG. HBI has entered into an alliance with Wins Bio for marketing the product. HBI would be marketing ERIG under the brand name 'AbhayRIG' through its 2,000-odd 'Abhay' clinics spread across the country.